These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35746502)

  • 21. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
    Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the coverage of inactivated enterovirus 71 (EV71) vaccine and adverse events following immunization with the EV71 vaccine among children from 2016 to 2019 in Guangzhou.
    Li ZQ; Qin ZQ; Tan HF; Zhang CH; Xu JX; Chen J; Ni LH; Yun XX; Cui M; Huang Y; Wang W; Zhang ZB
    Expert Rev Vaccines; 2021 Jul; 20(7):907-918. PubMed ID: 34036862
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
    Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
    Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Research progress on immune efficacy, safety, vaccination intention and immunization strategy of domestic enterovirus 71 vaccine after its marketing].
    Xu WJ; Chen EF
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Sep; 54(9):1010-1016. PubMed ID: 32907294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical safety assessment of a combined vaccine against Hepatitis a virus and enterovirus 71.
    Yang T; Liu B; Yue L; Xie T; Li H; Shao M; Yang R; Luo F; Long R; Xie Z
    Vaccine; 2021 Jun; 39(29):3952-3963. PubMed ID: 34088510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.
    Abdelnour A; Silas PE; Lamas MR; Aragón CF; Chiu NC; Chiu CH; Acuña TH; Castrejón Tde L; Izu A; Odrljin T; Smolenov I; Hohenboken M; Dull PM
    Vaccine; 2014 Feb; 32(8):965-72. PubMed ID: 24397906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination coverage estimates and utilization patterns of inactivated enterovirus 71 vaccine post vaccine introduction in Ningbo, China.
    Ye L; Chen J; Fang T; Ma R; Wang J; Pan X; Dong H; Xu G
    BMC Public Health; 2021 Jun; 21(1):1118. PubMed ID: 34112128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.
    Nguyen TT; Chiu CH; Lin CY; Chiu NC; Chen PY; Le TTV; Le DN; Duong AH; Nguyen VL; Huynh TN; Truong HK; Phan TL; Nguyen TTT; Shih SR; Huang CG; Weng YJ; Hsieh EF; Chang S; Chen C; Tai IC; Huang LM
    Lancet; 2022 Apr; 399(10336):1708-1717. PubMed ID: 35427481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants.
    Deichmann KA; Ferrera G; Tran C; Thomas S; Eymin C; Baudin M
    Vaccine; 2015 May; 33(20):2379-86. PubMed ID: 25765966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso.
    Sirima SB; Ouedraogo A; Barry N; Siribie M; Tiono AB; Nébié I; Konaté AT; Berges GD; Diarra A; Ouedraogo M; Soulama I; Hema A; Datta S; Liang Y; Rotrosen ET; Tracy JK; Jamka LP; Neuzil KM; Laurens MB
    Int J Infect Dis; 2021 Jan; 102():517-523. PubMed ID: 33176205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trial.
    Zhang W; Kong Y; Jiang Z; Li C; Wang L; Xia J
    Hum Vaccin Immunother; 2016 Apr; 12(4):922-30. PubMed ID: 26837471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity, safety, and lot consistency of a novel inactivated enterovirus 71 vaccine in Chinese children aged 6 to 59 months.
    Hu YM; Wang X; Wang JZ; Wang L; Zhang YJ; Chang L; Liang ZL; Xia JL; Dai QG; Hu YL; Mao QY; Zhu FC; Song YF; Gao F; Chen JT
    Clin Vaccine Immunol; 2013 Dec; 20(12):1805-11. PubMed ID: 24108780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
    He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
    Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.
    Nakayama T; Eda M; Hirano M; Goto W
    Hum Vaccin Immunother; 2019; 15(5):1139-1144. PubMed ID: 30724658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
    Zhu FC; Liang ZL; Li XL; Ge HM; Meng FY; Mao QY; Zhang YT; Hu YM; Zhang ZY; Li JX; Gao F; Chen QH; Zhu QY; Chu K; Wu X; Yao X; Guo HJ; Chen XQ; Liu P; Dong YY; Li FX; Shen XL; Wang JZ
    Lancet; 2013 Mar; 381(9871):1037-45. PubMed ID: 23352749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
    Klein NP; Weston WM; Kuriyakose S; Kolhe D; Howe B; Friedland LR; Van Der Meeren O
    Vaccine; 2012 Jan; 30(3):668-74. PubMed ID: 22064267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial.
    Gillet Y; Habermehl P; Thomas S; Eymin C; Fiquet A
    BMC Med; 2009 Apr; 7():16. PubMed ID: 19366435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.